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VGF is a propeptide of 617 amino acids expressed throughout the central and the
peripheral nervous system. VGF and peptides derived from its processing have been
found in dense core vesicles and are released from neuronal and neuroendocrine
cells via the regulated secretory pathway. Among VGF-derived neuropeptides, TLQP-
21 (VGF556−576) has raised a huge interest and is one of most studied. TLQP-21 is a
multifunctional neuropeptide involved in the control of several physiological functions,
potentially including energy homeostasis, pain modulation, stress responsiveness
and reproduction. Although little information is available about its receptor and the
intracellular mechanisms mediating its biological effects, recent reports suggest that
TLQP-21 may bind to the complement receptors C3aR1 and/or gC1qR. The first aim
of this study was to ascertain the existence and nature of TLQP-21 binding sites in
CHO cells. Secondly, we endeavored to characterize the ligand binding to these sites by
using a small panel of VGF-derived peptides. And finally, we investigated the influence of
TLQP-21 on selected intracellular signaling pathways. We report that CHO cells express
a single class of saturable and specific binding sites for TLQP-21 with an affinity and
capacity of Kd = 0.55 ± 0.05 × 10−9 M and Bmax = 81.7 ± 3.9 fmol/mg protein,
respectively. Among the many bioactive products derived from the C-terminal region of
VGF that we tested, TLQP-21 was the most potent in stimulating intracellular calcium
mobilization in CHO cells; this effect is primarily due to its C-terminal fragment (HFHH-
10). TLQP-21 induced rapid and transient dephosphorylation of phospholipase Cγ1
and phospholipase A2. Generation of IP3 and diacylglycerol was crucial for TLQP-21
bioactivity. In conclusion, our results suggest that the receptor stimulated by TLQP-
21 belongs to the family of the Gq-coupled receptors, and its activation first increases
membrane-lipid derived second messengers which thereby induce the mobilization of
Ca2+ from the endoplasmic reticulum followed by a slower store-operated Ca2+ entry
from outside the cell.
Keywords: TLQP-21, VGF, calcium, SOCE, STIM-1, receptor, CHO, HFHH-10
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Graphical Abstract | Schematic representation of TLQP-21 intracellular transduction mechanism in CHO cells. TLQP-21, by binding a G protein coupled
receptor (GPCR), activates PLCβ that in turn produces DAG and IP3 as second messengers. These molecules activate PKC, stimulate ERK1/2 phosphorylation and
induce intracellular Ca2+ release from the ER with the subsequent Ca2+ entry from outside the cell. Phosphorylation of AKT is probably a result of the increase in
cellular Ca2+ concentrations.
INTRODUCTION
The vgf gene, originally identified as a nerve growth factor
responsive gene in PC12 cells (Levi et al., 1985), has a tissue-
specific pattern of expression limited to specific neurons and to
specific endocrine cells (Salton et al., 2000; Levi et al., 2004).
In rodents, the vgf gene encodes a 617 amino acid protein
which is included in the extended granin family and is named
secretogranin VII (Bartolomucci et al., 2006). Secretogranin VII
itself is proteolytically processed to yield more than ten different
bioactive peptides (Trani et al., 2002). In the rat brain, VGF
is expressed in areas involved in the regulation of feeding,
reproduction, stress responsiveness and general homeostasis
(Salton et al., 2000; Levi et al., 2004; Razzoli et al., 2012), and
VGF-derived peptides have been found significantly decreased in
some neurodegenerative diseases (Carrette et al., 2003; Ruetschi
et al., 2005; Cocco et al., 2010). VGF immunoreactivity was, as
well, reported in gonadotroph and lactotroph cells in the rat
anterior pituitary (Ferri et al., 1995).
Among several bioactive peptides derived from VGF, TLQP-
21 (VGF556−576) is a 21 amino acid peptide which has been
immunopurified from brain tissues (Bartolomucci et al., 2006).
Despite many efforts to characterize the physiological effects of
TLQP-21, little is known about its molecular targets. Nonetheless,
adipocytes express a high affinity binding site for TLQP-21 and
in these cells TLQP-21 stimulates a pro-lipolytic effect (Possenti
et al., 2012). Moreover, we have recently demonstrated TLQP-
21 binding sites on CHO cells through the use of Atomic Force
Microscopy (Cassina et al., 2013). Interestingly, the rat ovary
express high levels of TLQP-21, which has been proposed to
affect female reproduction by modulating pituitary LH release
(Aguilar et al., 2013; Noli et al., 2014) The statistical distribution
of the attractive force between TLQP-21 and its binding site
is indicative of a single class of binding sites. This presence
of a TLQP-21 binding site in these cells is consistent with
their unique dose- and time-dependent increases of intracellular
calcium (Ca2+) mobilization in response to TLQP-21 (Cassina
et al., 2013). TLQP-21 stimulation of intracellular Ca2+ was
concentration-dependent, whereas LRPS-21 (a scrambled control
peptide that contains the same amino acids residues of TLQP-
21 but rearranged in a random order to prevent homology
with other published proteins) did not stimulate Ca2+ increases
in CHO cells, confirming the specificity of TLQP-21 effects.
Furthermore, N38 cells, which do not respond to TLQP-21,
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do not express binding sites for TLQP-21 in the Atomic Force
Microscopy measurements (Cassina et al., 2013).
It has recently been proposed that the complement component
3a receptor 1 (C3aR1) mediates TLQP-21 signaling in CHO
cells, and that TLQP-21 could be a natural agonist of this
receptor (Hannedouche et al., 2013). Noteworthy, it has been
reported that the stimulation of CHO cells with TLQP-21
did not induce any measurable intracellular Ca2+ increase
unless cells were subjected to a strong priming with 100 µM
ATP (Hannedouche et al., 2013). Other authors have also
reported that in rat macrophages TLQP-21 binds specifically
to the complement component C1q receptor (gC1qR) (Chen
et al., 2013). Interestingly, gC1qR and C3aR1 are receptors for
complement protein and it is possible that TLQP-21 interacts
with both receptors; however, which receptor mediates the effects
of TLQP-21 is still object of debate.
Since TLQP-21 is emerging as a novel target for obesity-
associated disorders (Bartolomucci et al., 2006; Possenti et al.,
2012), diabetes (Stephens et al., 2012), neuropathic pain (Chen
et al., 2013; Fairbanks et al., 2014) and other human pathologies
(Cocco et al., 2010), the purpose of this study was to better
characterize the binding site for TLQP-21 in CHO cells,
investigating its binding characteristics and the intracellular
pathways activated by the peptide-receptor interaction. The data
presented here clearly indicate that TLQP-21 binds to a single
class of receptors, probably belonging to the family of the
Gq-coupled receptors, and stimulates intracellular Ca2+ release
primarily from the endoplasmic reticulum (ER).
MATERIALS AND METHODS
Chemicals
TLQP-21 (TLQPPASSRRRHFHHALPPAR), YATL-23 (YATLQ
PPASSRRHFHHALPPAR), TLQP-62 (TLQPPASSRRRHFHHA
LPPARHHPDLEAQARRAQEEADAEERRLQEQEELEN-YIEH
VLLHRP), TLQP-8 (TLQPPASS), HFHH-10 (HFHHALPP
AR), HHPD-41 (HHPDLEAQARRAQEEADAEERRLQEQEELE
NYIEHVLLHRP), and LRPS-21 (LRPSHTRPAHQSFARP
LHRPA) have been synthesized by us using conventional solid
phase synthesis.
Cyclosporine A (CsA), thapsigargin (TG), U73122, 2-
Aminoethyl diphenylborinate (2-APB), SKF-96365, YM-58483,
and EGTA were purchased from Sigma–Aldrich (St Louis, MO,
USA). Unless otherwise specified, all other reagents were from
Sigma–Aldrich.
Cell Cultures
CHO cells were cultured in HAM’S F12 medium supplemented
with 10% heat-inactivated foetal bovine serum (FBS), 100 IU/ml
penicillin, 100 µg/ml streptomycin, and 2 mM L-glutamine (all
Euroclone, Pero, Italy) under standard cell culture conditions (at
37◦C, in 5% CO2).
Intracellular Ca2+ Mobilization Assay
CHO cells were plated at 20.000 cells/well into black walled,
clear bottom 96-well plate (Corning, Germany) and cultured
one day up to 80–90% of confluence. Prior to assay, cells
were incubated in dark conditions with 100 µl of Hank’s
Balanced Salt Solution (HBSS) containing 20 mM HEPES,
2.5 mM probenecid and 4.5 µM FLUO-4 NW (Molecular
Probes, Eugene, OR, USA) at 37◦C and 5% CO2 for 45 min.
Fluorescence emissions were measured with the multilabel
spectrophotometer VICTOR3 (Perkin Elmer, MA, USA) at
485/535 nm (excitation/emission filters) every 0.5 s for the
20 s preceding and the 60 s following the stimulation. TLQP-
21, TLQP-62, TLQP-8, HHPD-41, HFHH-10, and LRPS-21
were diluted in HBSS solution and injected into the wells
by an automated injector system. The nature of Ca2+ stores
involved in TLQP-21 action was investigated preincubating
cells with TG (2 µM, 20 min), an inhibitor of the Ca2+-
ATPase pump responsible for sequestering Ca2+ in the ER
(Feng et al., 2008), or CsA (2 µM, 15 min), an inhibitor of
the mitochondrial permeability transition pore (PTP) (Liantonio
et al., 2007). To ascertain whether phospholipase C (PLC) and
inositol trisphosphate receptors (IP3R) were involved in TLQP-
21 mechanism of action, cells were incubated with a specific PLC
inhibitor (U73122, 10 µM for 10 min) and a IP3R antagonist
(2-APB, 75 µM for 15 min) before the injection of TLQP-21
(Macmillan and McCarron, 2010; Li et al., 2013). Depletion
of Ca2+ from the ER leads to Ca2+ entry from outside the
cell by activation of Store-Operated Channels (SOCs). Again,
to assess the involvement of this pathway, CHO cells were
incubated with selective antagonists of this pathway (SKF-96365
and YM-58483 10 µM for 20 min, EGTA 1 mM for 30 min)
before the injection of TLQP-21 (Ishikawa et al., 2003; Li et al.,
2013).
TLQP-21 Binding Assay
Binding of TLQP-21 to crude membranes (30,000 × g pellet)
obtained from CHO cells was carried out using [125I]-
YATL-23 as ligand. YATL-23 was radioiodinated (specific
activity, 2000 Ci/mmol) using the lactoperoxidase method
(Muccioli et al., 1998; Muccioli et al., 2001) by Perkin
Elmer (Milan, Italy) and purified by reverse phase high-
performance liquid chromatography. For the single point
binding assay, cell membranes (corresponding to 100 µg
membrane protein) were incubated in triplicate at 23◦C,
unless otherwise noted, for 4 h under constant shaking with
0.5 nM [125I]-YATL-23 in a final volume of 0.5 ml assay
buffer (50 mM Tris, 2.5 mM EGTA, 0.002% bacitracin,
0.1% bovine serum albumin, titrated to a final pH of 7.4
with HCl). Non-specific binding was measured in parallel
incubations with 1 µM unlabelled YATL-23 to displace
the radioligand. Similar results were obtained using TLQP-
21 to displace the radioligand. The binding reaction was
terminated by the addition of ice-cold assay buffer, followed
by rapid filtration through Whatman GF/B filters as previously
reported (Muccioli et al., 1998) and the radioactivity bound
to membranes was measured by a Packard auto-γ-counter.
Specific binding-values were calculated as the difference obtained
subtracting non-specific from total binding. Specific binding
was expressed as a percentage of the total radioactivity
added. For saturation binding studies, cell membranes were
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incubated with various concentrations of the radioligand (0.03–
4 nM). Competition studies were performed by incubating cell
membranes (150 µg/tube) with 1 nM [125I]-YATL-23 with or
without various concentrations (from 10 pM to 0.1 µM) of
unlabelled YATL-23, TLQP-21, or LRPS-21. Data were plotted
and curves fit using the GraphPad Prism software version
4 (GraphPad Software, San Diego, CA, USA) assuming that
the binding was due to a single class of binding sites, thus
allowing determination of the maximum binding capacity (Bmax),
dissociation constant (Kd), Hill slope and concentration of the
competitor causing 50% inhibition (IC50) of specific radioligand
binding.
Phosphorylation of Cellular Kinases
CHO cells were plated 24 h before time course experiments
in 35 mm dishes at 70% confluence. After three washes with
medium w/o serum, cells were serum-starved for 1 h. Time
course experiments were performed and after quick removal of
the medium the reaction was stopped by placing the dish on ice
and adding 100 µl of ice-cold lysis buffer (50 mM Tris-HCl, pH
7.5, 150 mM NaCl, 10 mM EDTA) containing a protease inhibitor
cocktail and PhosphoStop inhibitor cocktail (Roche Diagnostic,
Mannheim, Germany).
Cells were stored at –80◦C until further processing. Cells
were harvested and equivalent amounts of cell extracts
(corresponding to approximately 200.000 cells) were run
on NuPAGE precast 4–12% gradient gels (Invitrogen, USA)
and transferred to a polyvinylidene difluoride (PVDF)
membrane (Amersham). After staining with Ponceau S to verify
uniformity of protein load/transfer, membranes were analyzed
for immunoreactivity. Incubation with primary antibodies
(anti-phospho-AMPK (Thr172); anti-phospho-AKT (Ser473);
anti-phospho-ERK1/2 (Thr202/Tyr204); anti-phospho-PKC
(Ser660); anti-phospho-PLA2 (Ser505); anti-phospho-JNK
(Ser63); and anti-phospho-PLCγ 1 (Tyr783) rabbit polyclonal
antibodies; Cell Signaling Technology, Danvers, MA, USA) at
1:1.000 dilution was performed overnight at 4◦C (Petrocchi et al.,
2010). Incubation with peroxidase-coupled secondary antibodies
(Amersham, Arlington Heights, IL, USA; now GE; 1:5.000)
was performed for 1 h at room temperature. Immunoreactivity
was developed by enhanced chemiluminescence (ECL system;
Amersham GE Healthcare, UK). Two parallel gels were
run for each experiment and with probes for different anti-
phosphorylated protein antibodies as indicated, avoiding
stripping protocols. The gels were normalized with anti-β-actin
monoclonal antibodies (Sigma). β-actin was chosen since we
have previously observed that its levels remained stable in time,
wherease those of α-tubulin decreased over time (Petrocchi et al.,
2010).
Statistical Analysis
Values are expressed as mean ± SEM. The statistical significance
of differences between groups was evaluated with Tukey–
Kramer’s t-test for multiple comparisons, preceded by the
analysis of variance (ANOVA). Where appropriate, F-values and
degrees of freedom (DF) are indicated in the legend of figures.
A P-value of less than 0.05 was considered significant.
RESULTS
TLQP-21 Stimulates Intracellular Ca2+
Levels in CHO Cells
CHO cells were incubated in vitro with increasing concentrations
(1 nM–10 µM) of TLQP-21. TLQP-21 (0.1 µM–10 µM) evoked
acute and significant increases (P < 0.05) in intracellular Ca2+
levels in CHO cells (Figure 1A); by comparison, LRPS-21 tested
at the concentration interval of 1 nM–10 µM did not stimulate
Ca2+ levels in CHO cells (Figure 1A) thereby confirming the
specificity of TLQP-21 action.
In the next series of experiments, we investigated whether
CHO cells could respond to repeated TLQP-21 stimulations given
at 5 min intervals from each other. Levels of free intracellular
Ca2+ increased sharply upon the first challenge with 10 µM
TLQP-21, whereas 5 min later a second application of 10 µM
TLQP-21 induced only a blunted increase in cell fluorescence;
no effects were observed when 5 min later 10 µM TLQP-21 was
applied a third time (Figure 1B). A final challenge with 10 µM
ATP to check for cell viability was not affected (data not shown).
Calcium Mobilizing Effects of
VGF-Derived Peptides
To gain further insight into the biological activity of VGF-
derived peptides, we stimulated CHO cells with different peptides
derived from the C-terminal region of VGF (Table 1). Natural
processing of TLQP-62 by prohormone convertases yields
TLQP-21 and HHPD-41 (Table 1). The 1 µM concentration
has been chosen to compare the effects of TLQP-62 and its
fragments on intracellular Ca2+ levels since this concentration
was close to the EC50 of TLQP-21 and could have allowed
to measure whether a test compound was less or more active
than TLQP-21. At concentrations as large as 1 µM TLQP-
62 failed to stimulate any significant increase in intracellular
Ca2+ levels (Figure 2). Similarly, HHPD-41 was also ineffective,
whereas TLQP-21 significantly stimulated intracellular calcium
mobilization (Figure 2). TLQP-21 itself is a substrate for
prohormone convertases to yield TLQP-8 (8 amino acids at
the N-terminal of TLQP-21) and HFHH-10 (10 amino acids at
the C-terminal of TLQP-21). HFHH-10 effectively stimulated an
intracellular Ca2+ increase in CHO cells; by comparison, TLQP-
8 at 1 µM induced only a slight and non-significant increase
in intracellular Ca2+. These results strongly suggest that the
C-terminal region of TLQP-21 is the sequence primarily involved
in the stimulation of its receptor on CHO cells (Figure 2).
TLQP-21 Binding Analysis in CHO Cells
The addition of Tyr-Ala (YA) amino acidic residues to TLQP-21
resulted in a peptide (YATL-23) with the same in vitro biological
activity of TLQP-21 in CHO cells (data not shown).
Given the evidence of intracellular Ca2+mobilization induced
by TLQP-21 in CHO cells, we investigated the presence of
specific TLQP-21 binding sites on CHO cell membranes by
radioreceptor assay using [125I]-YATL-23 as a ligand. The specific
binding of [125I]-YATL-23 to cell membranes varied with both
incubation time and temperature. Specific binding increased
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FIGURE 1 | TLQP-21 stimulation of intracellular Ca2+ levels in CHO cells. (A) Cells were loaded with FLUO-4 NW and fluorescence emissions were measured
at 485/535 nm (excitation/emission filters) every 0.5 s for the 60 s following injection of the stimuli. TLQP-21 was applied at concentrations ranging from 1 nM to
10 µM. Ca2+ mobilizing activity of TLQP-21 is plotted in terms of maximal response obtained at each given concentration in CHO cells. To ascertain the specificity
of the effects, cells were also challenged with 1 nM–10 µM LRPS-21, a scrambled peptide containing the same amino acid residues of TLQP-21. (B) Effects of
repeated stimulation with TLQP-21 on intracellular Ca2+ levels in CHO cells. 10 µM TLQP-21 was applied three times at 5 min intervals. Fluorescence was recorded
every 0.5 s. Results are the means ± SEM of measurements obtained in at least six different wells for each experiment. All experiments have been repeated at least
three times.
TABLE 1 | Aminoacidic sequence of peptides of the C-terminal region of VGF.
VGF-derived peptides
TLQP-62 TLQPPASSRRRHFHHALPPARHHPDLEAQARRAQEEADAEERRLQEQEELENYIEHVLLHRP
TLQP-21 TLQPPASSRRRHFHHALPPAR
HHPD-41 HHPDLEAQARRAQEEADAEERRLQEQEELENYIEHVLLHRP
TLQP-8 TLQPPASS
HFHH-10 HFHHALPPAR
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
-
TLQP-62 is the largest peptide encoded in the C-terminal sequence of VGF. Shorter peptides could be processed from its sequence. Dashed lines indicate the putative
sites for endoproteolytic cleavage.
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FIGURE 2 | VGF-derived peptides stimulation of intracellular Ca2+
levels in CHO cells. Cells were loaded with FLUO-4 NW and stimulated with
different VGF-derived peptides (1 µM). Ca2+ mobilizing activity of peptides is
plotted in terms of maximal response obtained at each given concentration in
CHO cells. Values plotted have been calculated as the difference between
stimulated fluorescence and pre-stimulated fluorescence divided by
pre-stimulated fluorescence (1F/F). Results are the means ± SEM of
measurements obtained in at least five different wells for each experiment.
ANOVA: F = 23.3; DF = 29. All experiments have been repeated at least three
times. ◦◦p < 0.01 vs. HBSS
with the duration of incubation and was greater at 23◦C when
compared to 4◦C after reaching equilibrium at 4 h (Figure 3A).
A study of specific binding as a function of membrane protein
concentration indicated that the binding was proportional to
protein content up to at least 100 µg/tube (Figure 3B). Specific
binding of [125I]-YATL-23 to cell membranes occurred over a
relatively wide range of pH. The maximal binding was observed
at pH 7.4 and declined to half-maximal value at pH 5.0 and 9.0
(Figure 3C). Therefore, all subsequent incubations were carried
out at pH 7.4 for 4 h at 23◦C with 100 µg membrane protein.
Brief exposure of CHO cell membranes to high temperature
(100◦C × 1 min) or enzymes that disrupt protein structure such
as trypsin (50 µg/ml × 5 min) caused the loss of the specific
binding of [125I]-YATL-23, suggesting that protein integrity is
functionally important in the binding site (Figure 3D).
Experiments using various concentrations of [125I]-YATL-
23 indicated the presence of a saturable and specific binding
associated with minor low non-specific binding (Figure 4A).
Scatchard transformation of the specific binding data (Figure 4B)
yielded a linear Scatchard plot with Hill slope close to 1
(Figure 4C), indicating the existence of a single class of binding
sites. The calculated Kd and Bmax values (means ± SEM of
three independent experiments) were 0.55± 0.05× 10−9 M and
81.7 ± 3.9 fmol/mg protein, respectively, and the Hill slope was
1.07± 0.1.
Unlabelled YATL-23 and TLQP-21 competed in a
concentration-dependent manner with [125I]-YATL-23 for
binding sites in CHO membranes (Figure 5). The IC50 values,
calculated according a one-site binding model (means ± SEM of
three independent experiments), were 1.2 ± 0.06 × 10−9 M for
YATL-23 and 0.98 ± 0.06 × 10−9 M for TLQP-21. The results of
these competition binding studies also revealed that the binding
of [125I]-YATL-23 to CHO membranes was specific and was
not inhibited by LRPS-21, the scrambled peptide made using
the same amino acidic residues of TLQP-21 (Figure 5). These
findings provide evidence that CHO cells contain significant
amounts of TLQP-21 binding sites showing typical features of
ligand-receptor interaction.
Intracellular Transduction Mechanisms
Activated by TLQP-21
It is known that Ca2+ stores, such as ER and mitochondria,
dynamically participate in generation of cytoplasmic Ca2+
signals (Verkhratsky and Petersen, 1998). We therefore studied
the possible implication of these intracellular organelles in the
increase of intracellular Ca2+ levels induced by TLQP-21. The
involvement of the ER was investigated using TG, which inhibits
the Ca2+-ATPase pump responsible for sequestering Ca2+ in
the ER and depletes the store by irreversibly preventing its
refilling. As shown in Figure 6A, TG reduced the TLQP-21-
mediated increase of intracellular Ca2+, causing a 56% reduction
after 20 min preincubation time. To rule out the possibility that
Ca2+ release from the mitochondria could also be involved,
we evaluated the effect of TLQP-21 in the presence of CsA,
an inhibitor of the mitochondrial PTP (Chernyak, 1997). The
incubation of CHO cells with 2 µM CsA did not modify the
basal levels of intracellular Ca2+ and a subsequent stimulation
with 1µM TLQP-21 induced a significant increase in intracellular
Ca2+ levels (Figure 6A). These results indicate that TLQP-21
stimulated Ca2+ release primarily from the ER store, whereas
release of Ca2+ from the mitochondria appeared not involved in
this mechanism of action.
In many cellular systems, PLC activation and subsequent
IP3 production is the transduction pathway regulating the
release of Ca2+ from ER. U73122 is an aminosteroid that
is reported to act as a specific inhibitor of PLC (Bleasdale
et al., 1990) and it is widely used as a quick test for the
involvement of PLC in a signaling pathway. To test whether
TLQP-21 induces Ca2+ mobilization through a PLC-dependent
mechanism, CHO cells were incubated for 10 min with
10 µM U73122. Results demonstrate that U73122 induced a
dramatic reduction, about 82%, of TLQP-21 stimulation of
intracellular Ca2+ mobilization (Figure 6B). As a further
confirmation, CHO cells were pre-incubated for 15 min with
75 µM 2-APB, which rapidly inhibits IP3R-mediated Ca2+
release. Treatment with 2-APB strongly affect TLQP-21 activity,
causing a decrement of intracellular Ca2+ mobilization of
about 79% (Figure 6B). As previously reported, depletion
of Ca2+ from the ER causes the activation of stromal
interaction molecule (STIM) proteins that, translocating into
junctions formed between the ER and the plasma membrane
(PM), activate the highly calcium-selective Orai channels to
homeostatically balance intracellular calcium (Soboloff et al.,
2012). To assess the role of this pathway, CHO cells were
pretreated with a STIM-mediated Ca2+ inhibitor (SKF-96365),
an inhibitor of Orai channels (YM-58483) or an extracellular
Ca2+ chelator (EGTA) before stimulation with 1 µM TLQP-21.
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FIGURE 3 | Specific binding of [125I]-YATL-23 to CHO cell membranes as a function of the length of assay incubation at 23◦C or 4◦C (A), of the amount
of membrane protein (B), of pH of the incubation medium (C) and after membrane treatment at 100◦C or with trypsin (D). Values are means ± SEM of three
independent experiments.
We observed a statistically significant decrement in TLQP-21-
mediated intracellular Ca2+ mobilization (Figure 6C), of about
36, 27, and 45% after treatment with SKF-96365, YM-58483, and
EGTA, respectively.
Next, we measured the effects of TLQP-21 treatment on
phosphorylation of intracellular signaling effectors. After 1 h of
serum starvation, cells were exposed to 10 µM TLQP-21 for 0–
30 min (Figure 7). The 10 µM concentration was chosen because
it elicited a stimulation near to maximal on intracellular Ca2+
mobilization (Figure 1). TLQP-21 induced a prompt increase of
phospho-AKT (1–5 min) (Figure 7A) that remained significantly
higher than basal until 15 min after stimulation (Figure 7A).
A rapid and transient dephosphorylation of phospho-AMPK
and phospho-PLCγ1 occurred between 1 and 10 min after
stimulation with TLQP-21(Figures 7B,C). A similar trend was
seen also for phospho-PLA2, but dephosphorylation reached
statistical significance only at 2 min (Figure 7D). Interestingly,
PKC phosphorylation increased after 2 min and lasted until
15 min from stimulation with TLQP-21 (Figure 7D). ERK1/2
phosphorylation increased significantly at 2 min, reached a
peak at 5 min and thereafter returned to basal (Figure 7F).
No effects were induced on phospho-JNK levels (data not
shown). A possible limitation of these determinations is
that sample loading was normalized using the corresponding
β-actin levels and not the levels of the unphosphorilated
protein.
DISCUSSION
The molecular mechanisms of TLQP-21 action at the cellular
level are still an object of debate, although this peptide could
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FIGURE 4 | Representative saturation isotherms, Scatchard and Hill plot of [125I]-YATL-23 binding to CHO cell membranes. (A) Experiments were
performed by incubating a fixed amount of membrane proteins with increasing concentrations of radiolabelled YATL-23, either alone (total binding) or together 1 µM
unlabelled YATL-23 (nonspecific binding), respectively. Specific binding values were obtained subtracting nonspecific binding from total binding. (B) The saturation
curve of specific binding was analyzed by Scatchard analysis. Values of Kd = 0.55 ± 0.05 × 10-9 M and Bmax = 81.7 ± 3.9 fmol/mg protein were calculated using
data obtained in three independent experiments. (C) Hill plot of the same data. The calculated Hill slope of 1.07 ± 0.1 is indicative of a single class of binding sites.
FIGURE 5 | Representative competition binding curves for
[125I]-YATL-23 to CHO cell membranes by the indicated competitors.
Binding is expressed as percentage of control (specific binding in the absence
of unlabelled competitor). Values are the means ± SEM of measurements
obtained in six different wells for each experiment.
represent an important target to counteract human disorders,
including obesity and diabetes. Our results demonstrate that
TLQP-21 is a robust extracellular signal capable of promoting
a Ca2+-mediated transduction signal in CHO cells. TLQP-21 is
one of many bioactive products derived from post-translational
cleavage of the C-terminal region of VGF, a propeptide that
could be involved in psychiatric, neurologic and metabolic
disorders (Carrette et al., 2003; Ruetschi et al., 2005; Bartolomucci
et al., 2011; Busse et al., 2012). Although TLQP-21 has been
implicated in the regulation of energy balance, nociception,
gastric function, and several other physiologic functions, its
binding site and mechanisms of action remain largely unknown
(Bartolomucci et al., 2006; Rizzi et al., 2008; Chen et al.,
2013). We have investigated the ability of some VGF-derived
peptides to induce intracellular Ca2+ mobilization in CHO
cells. Our results show that: (i) TLQP-21 stimulates a sharp
increase in free intracellular Ca2+ levels; (ii) on this pathway
it is more active than other VGF-derived peptides; and (iii) its
C-terminal fragment, that corresponds to HFHH-10 peptide,
is the region primarily involved in the process of stimulating
intracellular Ca2+ mobilization. These results are consistent
with those indicating that the “hot spots” for TLQP-21 activity
are localized in its C-terminal region (Cero et al., 2014). The
N-terminal region of the peptide appears more tolerant to
modifications, since the introduction of Tyr-Ala (YA) amino
acidic residues (YATL-23) did not change the activity on
intracellular Ca2+ mobilization and the ability of the peptide to
bind the receptor. However, the N-terminal region of TLQP-21,
corresponding to the sequence of TLQP-8, is apparently devoid
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FIGURE 6 | Modulation of intracellular Ca2+ levels by TLQP-21 in the presence of different inhibitors in CHO cells. Cells were loaded with FLUO-4 NW
and treated with different inhibitors before the stimulation with 1 µM TLQP-21. (A) CsA (2 µM, 15 min), a mitochondrial PTP inhibitor, did not affect TLQP-21 Ca2+
stimulation as did TG (2 µM, 20 min), an inhibitor of the ER Ca2+-ATPase. ANOVA: F = 23.2; DF = 46. (B) The PLC-inhibitor U73122 (10 µM, 10 min) and the IP3R
antagonist 2-APB (75 µM, 15 min) strongly reduced TLQP-21 stimulation of intracellular Ca2+ mobilization. ANOVA: F = 154.4; DF = 35. (C) SKF-96365 (10 µM,
20 min), YM-58483 (10 µM, 20 min) and EGTA (1 mM, 30 min), inhibitors of the SOCs pathway, affect significantly TLQP-21 effect. ANOVA: F = 20.4; DF = 49.
Graphs show the means ± SEM of measurements obtained in at least six different wells for each experiment. All experiments have been repeated at least three
times. ◦◦p < 0.01 vs. HBSS; ∗p < 0.05 and ∗∗p < 0.01 vs. TLQP-21.
of any activity on intracellular Ca2+ mobilization. Interestingly,
molecular dynamics simulations have revealed that TLQP-21 is
characterized by a highly flexible nature that fluctuates between
many conformations, spanning from a long helical to a more
compact form (Chakraborty et al., 2015). Another factor adding
complexity to the interpretation of the ability of VGF-derived
fragments to activate their receptor is the demonstration that
TLQP-21 undergoes a folding-upon-binding transition upon
receptor binding (Cero et al., 2014). Further studies are needed to
understand whether HFHH-10 satisfies the random coil to helix
transitions needed for activating G-protein coupled receptors
(Shoichet and Kobilka, 2012).
The results that we have obtained in this research clearly
demonstrated that TLQP-21 interacts with a single class of
binding site expressed on CHO cell membranes, further
confirming those observations that we have previously reported
using Atomic Force Microscopy (Cassina et al., 2013). It is
interesting that the membranes of CHO cells contain significant
amounts of TLQP-21 binding sites and this cell line can be a
useful in vitro model to study TLQP-21 mechanisms of action. In
our setting, TLQP-21 efficiently stimulated intracellular calcium
levels in CHO cells without the need of ATP priming previously
reported (Hannedouche et al., 2013). Ca2+ is a highly versatile
second messenger involved in a variety of intracellular signaling
pathways, including gene regulation, proliferation and cell death.
Repeated exposure to TLQP-21 resulted in a reduced response,
probably indicating a decrease in number of receptors available or
a decreased activity of intracellular signaling pathways involved.
Interestingly, TLQP-21 induced a specific desensitization to
subsequent TLQP-21 treatments, but not to ATP, and these data
are consistent with those reported in rat primary macrophages
and cerebellar granule cells (Severini et al., 2008; Chen et al.,
2013).
We have also shown that TLQP-21 stimulation induced an
increase of cytoplasmic Ca2+ levels that was determined by
release of Ca2+ from intracellular stores. In particular, our
studies indicate that in CHO cells Ca2+ is released mainly
from the ER stores, as demonstrated by the treatment with
TG, a Ca2+-ATPase pump inhibitor that depletes the ER store
by preventing its refilling (Thastrup et al., 1989), whereas
Ca2+ release from the mitochondria did not appear involved.
Our results also indicate that Ca2+ mobilization stimulated
by TLQP-21 is triggered by the activation of PLC, since
pretreatment of the cells with U73122, a known PLC inhibitor,
induced a significant reduction of Ca2+ mobilization. Western
blotting determinations indicated that TLQP-21 up-regulated
the phosphorylation levels of ERK1/2, PKC and AKT in CHO
cells. These kinases are activated by the dual phosphorylation
of neighboring threonine and tyrosine residues in response to
extracellular stimuli (Nadeau and Landry, 2007) Furthermore,
our results show that TLQP-21 induced a rapid and transient
dephosphorylation of AMPK, PLCγ1, and PLA2, whereas the
phosphorylation state of JNK was not altered. The intricate
balance of phosphorylation by kinases and dephosphorylation
by phosphatases is essential for maintaining signal transduction
networks in cells (Barford et al., 1998). The rapid increase
in the mobilization of intracellular Ca2+ is at least in part
dependent on the PLCγ family of proteins, including PLCγ1 and
PLCγ2 (Clapham, 2007). It is possible that the dephosphorylation
of PLCγ1 that we have observed could be involved in the
mechanisms by which TLQP-21 induced a clear desensitization
to subsequent TLQP-21 treatments. These results suggest that
the receptor stimulated by TLQP-21 should belong to the
family of the Gq-coupled receptors. It is widely accepted
that the IP3R on the ER are an essential link between PLC
activation and initiation of Ca2+ release from the ER. We
have shown that pretreating the CHO cells with 2-APB, an
IP3Rs antagonist, the release of Ca2+ induced by TLQP-21 was
heavily reduced, further confirming that the binding of TLQP-
21 with its receptor activates the PLC pathway. Reportedly, rapid
Ca2+ depletion from the ER activates slower Ca2+ entry from
outside the cell (Hewavitharana et al., 2007). STIM and Orai
proteins are required for the store-operated Ca2+ entry process
(Liou et al., 2005; Roos et al., 2005). Consistently, we have
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FIGURE 7 | Western blot analysis of signaling phospho-activated proteins. Time course of 10 µM TLQP-21 treatment from 1 min up to 30 min. Equal
amounts of cell lysates were processed for Western blot analysis, using specific antibodies for the phosphorylated (active) forms of signaling molecules.
Abbreviations: pAMPK = phospho-AMPK (Thr172); pAKT = phospho-AKT (Ser473); pERK1/2 = phospho-ERK1/2 (Thr202/Tyr204); pPKC = phospho-PKC (Ser660);
pPLA2 = phospho-PLA2 (Ser505); and pPLCγ1 = phospho-PLCγ1 (Tyr783). To ensure equal loading, blots were also probed with anti-β-actin. (A–F) Results shown
are means ± SEM of at least five measurements obtained in five independent experiments. ∗p < 0.05 and ∗∗p < 0.01 vs. time 0. (G) representative images of the
blots.
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found an inhibition of TLQP-21-mediated Ca2+ release following
treatment with SKF-96365 and YM-58483, two specific STIM-
and Orai-inhibitors, respectively. PLC activation by TLQP-21 is
followed by an increase of PKC phosphorylation and, afterwards,
ERK1/2 phosphorylation.
Given the previous identification of two putative receptors
for TLQP-21, the C3aR1 in CHO and RAW264.7 cells, and the
gC1qR in rat brain membranes, primary microglia, macrophages,
and DRG neurons (Chen et al., 2013; Hannedouche et al.,
2013), we have attempted its pharmacological characterization
in CHO cells. We have also previously demonstrated the
existence of a high-affinity binding site for TLQP-21 in
white and brown adipocyte membranes, and adrenals, whose
exact nature remains still unknown (Possenti et al., 2012).
CHO cells could be a useful in vitro model to study the
interaction of VGF-derived peptides with a putative specific
binding site, but the possibility that different binding sites
could be expressed by other cell systems cannot be ruled out.
Understanding the mechanism of action of TLQP-21 could be
of great relevance since this neuropeptide is purported to play
important roles in the central nervous system and peripheral
tissues.
CONCLUSION
Our results suggest that TLQP-21 effects in CHO cells could be
mediated by a Gq-coupled receptor that quickly activates PLCβ,
that produces DAG and IP3 as second messengers. DAG activates
PKC that, in turn, stimulates ERK1/2 phosphorylation. On the
other hand, by binding IP3R on the ER, IP3 stimulates a sharp
increase of intracellular Ca2+ levels and the subsequent Ca2+
entry from outside the cell through STIM-Orai interaction (see
Graphical abstract). The CHO cell line can be proposed as a useful
model for developing new synthetic agonists and antagonists of
TLQP-21 receptor, which could help a better understanding of
the physiologic and pathological role of VGF-derived peptides.
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